TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23958289

Group type: EXPERIMENTAL
Intervention: Ultrasound guided brachial plexus block using lignocaine with adrenaline and levobupivicaine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Local anaesthetic infiltration with lignocaine and levobupivicaine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ultrasound guided brachial plexus block
Number of subjects: 126

Group type: COMPARATOR
Intervention: Local anaesthetic infiltration
Number of subjects: 126
Study: 21420587

Group type: EXPERIMENTAL
Intervention: Apodized multifocal IOL (Group B)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Full diffractive multifocal IOL (Group C)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Monofocal IOL (Group A)
Number of subjects: 106
Study: 19125045

Group type: EXPERIMENTAL
Intervention: Epinastine 0.05% twice a day plus rewetting drops as required (n = 75)
Number of subjects: 146
Study: 17564203

Group type: EXPERIMENTAL
Intervention: Indirect, nonspecific, non‐perceptual, conceptual primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect, conceptual information (category of farm animals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-linguistic dependent measure
Number of subjects: 0
Study: 15848653

Group type: EXPERIMENTAL
Intervention: DAC-TAC-MMF (tacrolimus with MMF and daclizumab induction therapy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAC-MMF (tacrolimus with mycophenolate mofetil)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAC-MMF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DAC-TAC-MMF
Number of subjects: 30
Study: 11338101

Group type: EXPERIMENTAL
Intervention: Vac-fix immobilization device
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard breast board technique
Number of subjects: 17

Group type: COMPARATOR
Intervention: Patient preference
Number of subjects: 17
Study: 9385484

Group type: EXPERIMENTAL
Intervention: Tiludronate formulation 9O1 (400 mg/d for 84 +/- 2 days)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tiludronate formulation 3C1 (400 mg/d for 84 +/- 2 days)
Number of subjects: 88
Study: 8737552

Group type: EXPERIMENTAL
Intervention: Max‐EPA (fish oil rich in polyunsaturated fatty acids)
Number of subjects: 46

Group type: COMPARATOR
Intervention: CRF patients on conservative treatment (Gp II)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 3 months post-renal transplant patients (Gp IV)
Number of subjects: 46
Study: 3232477

Group type: EXPERIMENTAL
Intervention: Constant infusion of a solution containing glucose (4%), sodium (40 mmol/l), and potassium (20 mmol/l) throughout the observation period
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-hour infusion of 10% glucose daily, with potassium and sodium solution in between
Number of subjects: 0
Study: 28474437

Group type: EXPERIMENTAL
Intervention: SRP + 0.75% boric acid gel (BA group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: SRP + placebo gel (placebo group)
Number of subjects: 39
Study: 29244851

Group type: EXPERIMENTAL
Intervention: Sevuparin
Number of subjects: 0
Study: 26006738

Group type: EXPERIMENTAL
Intervention: 2-week exercise programme (exercise-carrousel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-week social stimulation programme
Number of subjects: 0
Study: 23601918

Group type: EXPERIMENTAL
Intervention: Chronic ankle instability group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 22
Study: 22110624

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (started on the day of admission)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Late enteral feeding (started after 60 hours in adults or 36 hours in children)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with aspiration pneumonia
Number of subjects: 56
Study: 19363908

Group type: EXPERIMENTAL
Intervention: Tretinoin gel 0.05% (n=674)
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Vehicle (n=487)
Number of subjects: 1537

Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.1% (n=376)
Number of subjects: 1537
Study: 16469022

Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg twice daily for 12 weeks
Number of subjects: 658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study: 12964501

Group type: EXPERIMENTAL
Intervention: Tropisetron 0.05 mg/kg intravenously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Droperidol 15 micrograms/kg intravenously
Number of subjects: 40
Study: 10376458

Group type: EXPERIMENTAL
Intervention: MIST VR training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 8902249

Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1828963

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 on days 1, 8, 15, and 22 of radiation therapy
Number of subjects: 246

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 246
Study: 6338416

Group type: EXPERIMENTAL
Intervention: Propranolol (1.7 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phenobarbital (1.3 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29777228

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 78
Study: 26247613

Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 91
Study: 25675562

Group type: EXPERIMENTAL
Intervention: Acupuncture with filiform needle and warm needling therapy combined with positive functional exercise (CZ Dz)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints, warm needling and positive functional exercise
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints and distal acupoints, acupuncture with filiform needle and warm needling and positive functional exercise
Number of subjects: 192
Study: 23615577

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 42
Study: 20007927

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 119
Study: 19014765

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg twice daily (FP monotherapy)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Combination fluticasone 100 microg AM and salmeterol twice daily
Number of subjects: 285

Group type: COMPARATOR
Intervention: Season (spring, fall, or winter vs summer)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Average seasonal 5% reduction in AM peak expiratory flow
Number of subjects: 285
Study: 15836887

Group type: EXPERIMENTAL
Intervention: 5 mg rimonabant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg rimonabant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12841342

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg at the time of admission (group C+)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard therapy (group C−)
Number of subjects: 44
Study: 10442494

Group type: EXPERIMENTAL
Intervention: L-arginine infusion (290 mg/min/1.73 m2 for 1 h) in normal volunteers
Number of subjects: 26

Group type: COMPARATOR
Intervention: L-arginine infusion
Number of subjects: 26
Study: 7587923

Group type: COMPARATOR
Intervention: AO-128 (0.2 mg) with sucrose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AO-128 (0.03 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AO-128 (0.1 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2185006

Group type: EXPERIMENTAL
Intervention: Diabetes in Self-Control (DISC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Education (CE)
Number of subjects: 20
Study: 379369

Group type: EXPERIMENTAL
Intervention: Top-vented closed urinary drainage system
Number of subjects: 236

Group type: COMPARATOR
Intervention: Bag-vented drainage system
Number of subjects: 236
Study: 31874652

Group type: EXPERIMENTAL
Intervention: White noise
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: White noise + Glucose
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 396
Study: 27990776

Group type: EXPERIMENTAL
Intervention: Luseogliflozin with high carbohydrate (HC; 55% total energy carbohydrate) and high glycaemic index (HGI) meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luseogliflozin with high carbohydrate (HC; 55% total energy carbohydrate) and low glycaemic index (LGI) meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luseogliflozin with low carbohydrate (LC; 40% total energy carbohydrate) and HGI meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low carbohydrate (LC; 40% total energy carbohydrate) and HGI meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate (HC; 55% total energy carbohydrate) and HGI meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate (HC; 55% total energy carbohydrate) and low glycaemic index (LGI) meal
Number of subjects: 0
Study: 26695796

Group type: EXPERIMENTAL
Intervention: Low frequency and intermediate frequency descent type treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Flat type treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: High frequency descent type treatment
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Total deafness type treatment
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Patients with vertigo/dizziness
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Patients without vertigo/dizziness
Number of subjects: 1024
Study: 23392089

Group type: EXPERIMENTAL
Intervention: Independent determinants identified through multivariate analysis
Number of subjects: 2776

Group type: EXPERIMENTAL
Intervention: CRP lowering intervention
Number of subjects: 2776

Group type: COMPARATOR
Intervention: Conventional risk factors
Number of subjects: 2776
Study: 21869693

Group type: EXPERIMENTAL
Intervention: GW468816 (200 mg/d)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 19968217

Group type: EXPERIMENTAL
Intervention: Early rehabilitation group (no flexion or car riding restrictions)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard rehabilitation group (with restrictions to avoid hip flexion >90 degrees and car riding for the first month)
Number of subjects: 81
Study: 17828063

Group type: EXPERIMENTAL
Intervention: depo- and galvanophoresis with copper hydroxide-calcium
Number of subjects: 372
Study: 15169706

Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 6 months
Number of subjects: 63
Study: 11465650

Group type: EXPERIMENTAL
Intervention: Sodium chloride supplementation 2 g four times a day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 21
Study: 9467039

Group type: EXPERIMENTAL
Intervention: High-dose leucovorin (LV) administered weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimonthly high-dose LV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weekly high-dose LV with 5-fluorouracil (5-FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily x 5 LV with 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies for toxicity (delaying treatment, dose reduction, octreotide)
Number of subjects: 0
Study: 8649867

Group type: EXPERIMENTAL
Intervention: Ambulatory stapedectomy (admitted on the day of surgery, released 1-2 hours after procedure)
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-patient stapedectomy (admitted the day before surgery, discharged 24 hours after procedure)
Number of subjects: 20
Study: 1980266

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 1.1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 2.2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 4.4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride 2.2 mg and 4.4 mg
Number of subjects: 12
Study: 6259722

Group type: EXPERIMENTAL
Intervention: Oral Estramustine phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular polyestradiol phosphate plus oral ethinyl estradiol
Number of subjects: 0
Study: 30383289

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (100 mcg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Transversus abdominis plane block
Number of subjects: 130
Study: 28658358

Group type: EXPERIMENTAL
Intervention: Heliosit Orthodontic
Number of subjects: 53

Group type: COMPARATOR
Intervention: Transbond XT
Number of subjects: 53
Study: 25630368

Group type: COMPARATOR
Intervention: Lipid-based nutritional supplement without additional vitamins and minerals (LNS)
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement with additional vitamins and minerals (LNS-VM)
Number of subjects: 1815

Group type: COMPARATOR
Intervention: LNS
Number of subjects: 1815

Group type: EXPERIMENTAL
Intervention: LNS-VM
Number of subjects: 1815
Study: 23577271

Group type: EXPERIMENTAL
Intervention: Motor training (30 minutes of repeated maximum left thumb abduction) in the morning (8 AM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Motor training (30 minutes of repeated maximum left thumb abduction) in the evening (8 PM)
Number of subjects: 22
Study: 19854074

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no sitagliptin)
Number of subjects: 40
Study: 18355326

Group type: EXPERIMENTAL
Intervention: Insulin glargine without polysorbate-20 (R)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Insulin glargine with polysorbate-20 (T)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both formulations of insulin glargine
Number of subjects: 24
Study: 17240784

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 17
Study: 14647265

Group type: COMPARATOR
Intervention: mini-ICE+filgrastim
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: HiDAC+AMSA+filgrastim
Number of subjects: 38
Study: 10963159

Group type: EXPERIMENTAL
Intervention: Antegrade femoral nailing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Retrograde femoral nailing
Number of subjects: 68
Study: 8607393

Group type: EXPERIMENTAL
Intervention: Flecainide 200 mg (n = 97)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propafenone 450 mg (n = 103)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Flecainide (maximum 300 mg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propafenone (maximum 900 mg/day)
Number of subjects: 200
Study: 1790601

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 460

Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens
Number of subjects: 460
Study: 6791230

Group type: EXPERIMENTAL
Intervention: 10 mg oral diazepam
Number of subjects: 0
Study: 31701267

Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System™
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dynasplint Trismus System®
Number of subjects: 27
Study: 30679290

Group type: EXPERIMENTAL
Intervention: Advance care planning discussions facilitated by a trained health professional
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written information on advance care planning (current standard of care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advance care planning discussions
Number of subjects: 0
Study: 28623638

Group type: EXPERIMENTAL
Intervention: Taurolock‐U 25,000 (urokinase 25,000, taurolidine, citrate 4%) once a week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Taurolock™‐HEP500 (heparin 500 IU/mL, taurolidine, citrate 4%) after each hemodialysis session
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study: 25640807

Group type: EXPERIMENTAL
Intervention: Intensive/triple antiplatelet therapy for one month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline antiplatelets for one month
Number of subjects: 0
Study: 24171182

Group type: EXPERIMENTAL
Intervention: Propranolol 90 mg and Stabilization Splint (SS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Propranolol placebo and Stabilization Splint (SS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Propranolol 90 mg and Non-Occlusal Splint (NOS)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Propranolol placebo and Non-Occlusal Splint (NOS)
Number of subjects: 94
Study: 21108337

Group type: EXPERIMENTAL
Intervention: GBV-C infection among HIV-infected women
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: GBV-C infection among HIV-uninfected women
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Risk factors for GBV-C infection
Number of subjects: 1719

Group type: EXPERIMENTAL
Intervention: Clearance of GBV-C RNA among women with GBV-C infection
Number of subjects: 1719
Study: 19301691

Group type: EXPERIMENTAL
Intervention: Telmisartan (an ARB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of telmisartan and ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ramipril (an ACEI)
Number of subjects: 0
Study: 17550044

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (2 mg/kg 2 h before treatment and 1 mg/kg 20 min before treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Midazolam (0.50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (50 mg/kg) mixed with hydroxyzine (1.5 mg/kg) 20 min before treatment
Number of subjects: 54
Study: 14762748

Group type: EXPERIMENTAL
Intervention: Phase I surgery (hyoid suspension, palatal surgery, and/or genioglossus advancement)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Phase II surgery (maxillomandibular advancement)
Number of subjects: 57
Study: 11321604

Group type: EXPERIMENTAL
Intervention: Rowing exercise regimen (16-week duration)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 9495405

Group type: EXPERIMENTAL
Intervention: Becton‐Dickinson 27‐gauge, 119‐mm Whitacre
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Becton‐Dickinson 25‐gauge, 120‐mm Durasafe
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: International Medical Devices' 26‐gauge, 124‐mm Gertie Marx
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Becton‐Dickinson 27‐gauge, 120‐mm Durasafe
Number of subjects: 407

Group type: COMPARATOR
Intervention: All spinal needles
Number of subjects: 407
Study: 8056717

Group type: EXPERIMENTAL
Intervention: Pimobendan (2.5 or 5.0 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pimobendan
Number of subjects: 21
Study: 3241254

Group type: EXPERIMENTAL
Intervention: Adrenaline (15 mg/kg per min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Noradrenaline (30 ng/kg per min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (0.9% NaCl, 5.4 ml/h)
Number of subjects: 10
Study: 31847590

Group type: EXPERIMENTAL
Intervention: Reconstruction in elongated position
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Traditional carpal tunnel release
Number of subjects: 1050
Study: 29804902

Group type: EXPERIMENTAL
Intervention: Ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo plus endocrine therapy (oral tamoxifen 20 mg daily or letrozole 2.5 mg or anastrozole 1 mg daily, both with goserelin 3.6 mg subcutaneously every 28 days)
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 28372325

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation intervention (CORDIAL)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standardized Cognitive Training (active control)
Number of subjects: 16
Study: 25560779

Group type: EXPERIMENTAL
Intervention: Selective excavation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Stepwise excavation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 300
Study: 23938374

Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy treated women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Molecular markers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment related toxicities (mucositis, diarrhea, decreased absolute neutrophil count, elevated glucose, cholesterol)
Number of subjects: 0
Study: 21449676

Group type: EXPERIMENTAL
Intervention: Antidepressants other than paroxetine
Number of subjects: 131

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: rs1360780 within the FKBP5 gene
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 2677G>T in the ABCB1 gene
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: rs130058 SNP within the 5‐HTR1B gene
Number of subjects: 131
Study: 18155871

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg twice daily, could be reduced to 50 mg twice daily)
Number of subjects: 1435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1435
Study: 16271819

Group type: EXPERIMENTAL
Intervention: Both hemispheres engaged (pseudoword condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right hemisphere disengaged
Number of subjects: 0

Group type: COMPARATOR
Intervention: No asymmetry in processing non-words
Number of subjects: 0
Study: 14513241

Group type: COMPARATOR
Intervention: Atopic eczema group intervention program for parents of children aged 0-7 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atopic eczema group intervention program for parents and children aged 7-12 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atopic eczema group intervention program for youths aged 13-18 years
Number of subjects: 0